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A STUDY ON THE POTENTIAL OF ACTIVE CONSTITUENT FROM  
Senna spectabilis  IN TREATING Leishmania major INFECTION. 
 
 
 
  
    eishmaniasis affects millions of people each year. It consists of a 
group of tropical infections that are effecting human populations in 
mainly low-income countries. Visceral Leishmaniasis (VL) and Cutaneous 
Leishmaniasis (CL) are the main forms of Leishmaniasis which cause 
mortality, chronic disability and poverty. Leishmanasis is among three of 
most neglected diseases in the world, together with Human African 
Trypanosomiasis (HAT) and Chagas’ disease. These diseases are termed as neglected diseases because they are 
receiving very limited press attention as well as research funding as compared to HIV/AIDS, tuberculosis and 
malaria. In 2003, Drugs for Neglected Diseases Initiative (DNDi) which is a non-profit drug R&D agency focusing on 
developing new treatments for neglected diseases was established. Malaysia is one of seven founding partners from 
around the world who had joined the force, indicating our interest in tackling this global health issue. Cutaneous 
Leishmaniasis (CL), the most common form of leishmaniasis is a disease with a varied spectrum of clinical 
manifestations, which range from small cutaneous nodules to gross mucosal destruction. Leishmania major is the 
most commonly studied parasite for CL, and distributed in wide area of the world which are Central Asia, North 
Africa, Middle East and East Africa. 
  It is also commonly used in in vitro and animal models in antiparasite drug discovery studies as it is the first 
Leishmania species which the genome had been fully sequenced back in 2005. In the natural life cycle of Leishmania 
species, it is transmitted through the bites of infected female sandflies. When a sandfly takes a blood meal from the 
host, promastigotes are released (via saliva) into the skin and bloodstream which subsequently invade the host 
macrophage. Thus, the target for chemotherapy of leishmaniasis is the intracellular amastigotes in the mammalian 
host. Alternative approaches are needed because the majority of those infected live in countries which are not 
financially capable in market-driven drug discovery. Current treatments come together with side effects such as 
cardiotoxicity and nephrotoxicity, besides requiring a long course of treatment leading to the development of 
resistance on the parasites. 
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 In this study, antileishmanial properties from the constituents of a medicinal plant, Senna spectabilis were 
investigated using in vitro antileishmanial assays which were the first one established in Malaysia. Bioassay-guided 
isolation approach in this work resulted in further fractionation of the ethyl acetate extract with a series of 
chromatography processes which involved VLC, CC and flash CC which finally yielded the bioactive constituent 
against L. major with EC50 = 20.584 ± 1.65 µg/mL. The bioactive constituent was determined as piperidine alkaloid 
named (+)-spectaline based on the spectroscopic analysis mainly mass spectrometry (MS), infrared spectral (IR) and 
nuclear magnetic resonance (NMR). This natural compound showed cytotoxicity IC50 = 45.57 µg/mL or 0.14 ± 1.06 
µM and selectivity index, SI = 2.22 From this work, we have demonstrated that the compound (+)-spectaline isolated 
from S. spectabilis is active against in vitro L. major infection, via antileishmanial bioassay-guided isolation method 
developed in-house. The finding from this work hopefully will aid the drug development efforts for leishmaniasis 
treatment.This work has been published in the International Journal of Pharmacology, Phytochemistry and 
Ethnomedicine (IJPPE) , Vol 3, year 2016 with the title ‘(+)-Spectaline, a Piperidine Alkaloid from Senna spectabilis 
DC. Effective in Reducing the In Vitro Infection of Leishmania major’. 
 
